{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T18:36:46Z","timestamp":1770575806372,"version":"3.49.0"},"reference-count":29,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2009,6,23]],"date-time":"2009-06-23T00:00:00Z","timestamp":1245715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:p>Hepatitis C virus (HCV) infection has a high risk of liver cirrhosis and hepatocellular carcinoma at later stages. We recently identified a peptide derived from the HCV core protein capable of inducing both cellular and humoral responses to nearly all HCV\u2010positive patients in Japan with different human leukocyte antigen (HLA)\u2010class I\u2010A alleles. To assess the safety and immune responses to this novel peptide, we conducted a phase I dose\u2010escalation study of the vaccination for 26 HCV\u2010positive patients who were either non\u2010responders to the interferon\u2010based therapy (<jats:italic>n<\/jats:italic>\u00a0= 23) or refused it (<jats:italic>n<\/jats:italic>\u00a0=\u00a03). The regimen was well tolerated, with no severe vaccine\u2010related toxicity. Twenty\u2010five and 22 patients completed the first and second cycle vaccination (6 and 12 vaccine injections), respectively. After a series of six vaccine injections, peptide\u2010specific CTL activity was augmented in peripheral blood mononuclear cells from 15 of 25 patient samples, with an expected optimal dose of 1\u00a0mg peptide. After 12 vaccine injections, peptide\u2010specific IgG production was augmented in plasma from the majority of patients (15 of 22 patients) tested, but not in a dose\u2010dependent fashion. There were two HCV RNA responders with &gt;1 log declines. Among patients whose pre\u2010vaccination levels of alanine aminotransferase and alpha feto\u2010protein exceeded the normal ranges, a &lt;30% decrease was found in 7 of 24 and three of six patients, respectively. Because of its tolerability and higher rate of immune boosting, this protocol is recommended for a phase II study to investigate its clinical efficacy. (<jats:italic>Cancer Sci<\/jats:italic>\u00a02009; 100: 1935\u20131942)<\/jats:p>","DOI":"10.1111\/j.1349-7006.2009.01256.x","type":"journal-article","created":{"date-parts":[[2009,6,23]],"date-time":"2009-06-23T08:31:55Z","timestamp":1245745915000},"page":"1935-1942","source":"Crossref","is-referenced-by-count":35,"title":["Phase I clinical study of a peptide vaccination for hepatitis C virus\u2010infected patients with different human leukocyte antigen\u2010class I\u2010A alleles"],"prefix":"10.1111","volume":"100","author":[{"given":"Shigeru","family":"Yutani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobukazu","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Shichijo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Takedatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Itou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Kuromatu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Ide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Sata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyogo","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,9,14]]},"reference":[{"key":"e_1_2_7_2_2","unstructured":"Initiative for Vaccine Research: Hepatitis C.(Website on the internet).2006Available from URL:http:\/\/www.who.int\/vaccine_research\/diseases\/viral_cancers\/en\/index2.html#disease%20burden. World Health Organization Geneve Switzerland cited at July 6 2009."},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.37146"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.24.9524"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.2000.00221.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.06.026"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.02.058"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.08.005"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.69.4.2462-2470.1995"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117694"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000211340.88835.e7"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1348-0421.2006.tb03861.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1348-0421.2004.tb03546.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-007-0284-5"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20078"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.1999.540401.x"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050808"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.12.7852-7859.2005"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70126-9"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1117-3"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20572"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0559"},{"key":"e_1_2_7_23_2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0016-5085(97)70235-X","article-title":"Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections","volume":"112","author":"Bertoketti A","year":"1997","journal-title":"Gastroenterology"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.46.2.260"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70134-X"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.179.2.757"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.175.3.671"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/2053"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23056"},{"key":"e_1_2_7_30_2","first-page":"1065","volume-title":"Proceedings of the Eleventh International Histocompatibility Workshop and Conference","author":"Imanishi T","year":"1992"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2009.01256.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2009.01256.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T21:59:30Z","timestamp":1695938370000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2009.01256.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,14]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1111\/j.1349-7006.2009.01256.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2009.01256.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,14]]}}}